Clinical Trials Logo

Filter by:
NCT ID: NCT02475382 No longer available - Clinical trials for Non-squamous Non-Small Cell Lung Cancer

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen

CheckMate 169
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous (Sq) or non-squamous (non-Sq) non-small cell lung cancer (NSCLC) , Stage IIIB/IV and whose physicians believe that nivolumab treatment is appropriate.

NCT ID: NCT02475798 No longer available - Iliac Aneurysms Clinical Trials

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this extended study is to collect confirmatory safety and effectiveness data on the Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the commercially available Atrium iCASTâ„¢ covered stent in the treatment of aortoiliac and iliac aneurysms.

NCT ID: NCT02477345 No longer available - Liver Disease Clinical Trials

Compassionate Use of Omegaven IV Fat Emulsion

Start date: n/a
Phase: N/A
Study type: Expanded Access

This protocol involves the compassionate use of intravenous fish oil infusion, Omegaven. The protocol involves infants and children with parenteral nutrition-associated liver disease to enable the reversal of elevated serum liver enzymes and direct bilirubin (cholestasis).

NCT ID: NCT02480777 No longer available - Clinical trials for Sciatic Nerve Injury

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

Start date: n/a
Phase:
Study type: Expanded Access

The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells as a supplement along with nerve autograft (eg sural nerve) a few weeks after a severe injury to the sciatic nerve has occurred.

NCT ID: NCT02500082 No longer available - Clinical trials for Citrate Transporter Deficiency

Triheptanoin (UX007) to Treat Citrate Transporter Deficiency

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to determine whether triheptanoin (UX007) is effective in the treatment of neurological symptoms related to citrate transporter deficiency (SLC13A5 gene mutation).

NCT ID: NCT02510079 No longer available - Clinical trials for Sciatic Nerve Injury

Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.

Start date: n/a
Phase:
Study type: Expanded Access

The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells to augment sural nerve autografts after a severe, non-lacerating injury to the sciatic nerve has occurred.

NCT ID: NCT02531672 No longer available - Prostate Cancer Clinical Trials

Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to use a new imaging drug called 11C-choline that is used with a PET/CT scan to see prostate cancer when it cannot be seen well on other scans, such as bone scans, CT or MRI.

NCT ID: NCT02533219 No longer available - Clinical trials for Congenital Hyperinsulinism

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

[18F]-DOPA
Start date: n/a
Phase:
Study type: Expanded Access

The primary objective of this study is to evaluate the utility of [18F]-DOPA PET to provide improved presurgical planning and distinguish between focal and diffuse forms of HI. The investigators will perform descriptive analysis, relying on visual analysis to diagnose and localize a focal lesion. Our findings will be compared to surgical histopathology to determine sensitivity and specificity or this technique. The investigators will also track patient surgical outcomes, specifically whether the patient is surgically "cured" or still requires medical management to control residual hypoglycemia.

NCT ID: NCT02541643 No longer available - Multiple Myeloma Clinical Trials

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

Start date: n/a
Phase: N/A
Study type: Expanded Access

To provide elotuzumab treatment for single-patient use.

NCT ID: NCT02547675 No longer available - Clinical trials for Non-small Cell Lung Cancer

Rociletinib (CO-1686) USA Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+).